Tresmares backs UK dental lab group MediMatch's five-lab acquisition
What's the deal? Tresmares CapitalDealroom has a profile for this one. Try Dealroom → has provided a debt financing package to MediMatch Dental LaboratoryDealroom has a profile for this one. Try Dealroom →, a UK dental labs group backed by Queen's Park Equity (QPE)Dealroom has a profile for this one. Try Dealroom →, to fund its acquisition of five laboratories. Santander UKDealroom has a profile for this one. Try Dealroom → also supported the transaction with a revolving credit facility (RCF).
What does MediMatch do? Founded in 2006 by Hugo Van Loenen, the company supplies precision dental prosthetics to more than 3,000 dentists across the UK and continental Europe. It runs a proprietary workflow and case management system that lets dentists and suppliers commission, customise, and track dental work.
Why now? In May 2026, MediMatch acquired five laboratories previously part of a large dental group, adding onshore production capacity for high-end restoration work. Tresmares provided acquisition financing plus a committed facility for future M&A.
What's the endgame? "The market for dental labs remains fragmented, and there is an opportunity to create a scale player in the UK market," said Phil Arbour, senior partner at Tresmares Capital. The labs span the UK, with two in the South of England and two in the North.
Who's behind it? Tresmares Capital, established in Spain in 2020, opened its London office in September 2022 and now manages capital commitments above €3.3bn. Its direct lending strategy is sector-agnostic, targeting fast-growing businesses with €2m to €20m of EBITDA.
The signal: The deal reflects private capital's appetite for consolidating fragmented, specialist healthcare sectors. With QPE backing since 2025 and now a committed acquisition facility in place, MediMatch is positioned to keep buying up labs and build a UK market leader.
Read more: capital-riesgo.es
Image credit: Commander, U.S. 7th Fleet
